NCT01832922View on ClinicalTrials.gov

BR in Patients With CLL With Comorbidities and/or Renal Dysfunction

PHASE1CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

April 30, 2013

Primary Completion Date

April 27, 2015

Study Completion Date

November 28, 2016

Conditions
Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
Interventions
DRUG

Bendamustine

DRUG

Rituximab

Trial Locations (2)

02215

Dana Farber Cancer Institute, Boston

03750

Dartmouth-Hitchcock Medical Center, Norris Cotton Cancer Center, Lebanon

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Dartmouth-Hitchcock Medical Center

OTHER

NCT01832922 - BR in Patients With CLL With Comorbidities and/or Renal Dysfunction | Biotech Hunter | Biotech Hunter